Healthcare & Bioscience

The biopharmaceutical sector is an weighty and fast growing part of the wider international pharmaceutical industry, increasing healthcare products such as vaccines, monoclonal antibodies and recombinant proteins. This sector is forecast to grow to around 30% of the add up international pharmaceutical bazaar by 2015. Development and manufacturing of biopharmaceuticals poses actual technical challenges and the growth of the international bazaar in support of biopharmaceuticals is creating a important opportunity in support of the UK’s expertise in bioprocessing.

Proposals are sought in support of collaborative R&D projects which will develop novel technologies with the purpose of would reduce the period to clinic or bazaar of contemporary biopharmaceuticals and/or have an advantage to more cost efficient processes in support of the development and manufacture of protein therapeutics, monoclonal antibodies, vaccines and gene therapies.

These possibly will be: Industry-oriented basic examine; or functional R&D projects; or experimental development (technology validation) projects.

And interest science-to-business (S2B) or business-to-business (B2B) interactions. Projects be supposed to be businessled and project consortia be supposed to include next to slightest solitary partner with defined end-user needs. Funding from Research Councils is open in support of projects somewhere in attendance is a important superior quality academic factor and in actual in support of individuals projects with the purpose of display added price to their existing portfolios; by building on or being complementary to existing academic examine programmes, in support of illustration the Bioprocessing Industry Research Club

Scope in support of Applications

Proposals in support of collaborative R&D projects be supposed to focus on novel technologies with the purpose of would reduce the period to clinic or bazaar of contemporary biopharmaceuticals and/or have an advantage to more cost efficient processes in support of the manufactureof biopharmaceuticals.

The following areas will be considered a priority in support of this competition:

    * Protein therapeutics - plus the design through protein and glycoengineering, production, sanitization, formulation, approach and analysis of recombinant DNA-derived proteins

    * Monoclonal antibodies - plus antibody engineering and antibody air.

    * Vaccines - plus subunit vaccines, live vaccines, inactivated vaccines, chromosome vaccines, antigen discovery, vaccine development, formulation and approach and manufacture, adjuvants

    * Gene therapies - plus design of vectors, bioprocessing of vectors.

Technologies which get better prediction of toxicity and prediction and prevention of immunogenicity in biopharmaceutical development will plus get nearer contained by the scope of this call. Proposals which contact these areas from the perspective of engineering and real science will be as refreshing as individuals taking a more biological contact. Technologies in support of the development and manufacture of cell and tissue therapeutics are debarred from the scope of this competition.